Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W FRIEDBERG

Showing results (11-20 of 353) with videos related to

Pageof 36
Sort By:
The Oncologist|October 8, 2003
PET scans in the staging of lymphoma: current statusJonathan W Friedberg, Vaseem Chengazi
Current Hematologic Malignancy Reports|April 29, 2010
Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphomaManzurul A Sikder, Jonathan W Friedberg
Hematology/Oncology Clinics of North America|October 29, 2008
Diffuse large B-cell lymphomaJonathan W Friedberg, Richard I Fisher
Future Oncology (London, England)|January 15, 2021
Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomasPatrick M Reagan, Jonathan W Friedberg
Seminars in Hematology|April 3, 2008
Non-myeloablative radioimmunotherapy for non-Hodgkin's lymphomaJulia Schaefer-Cutillo, Jonathan W Friedberg
Health Affairs (Project Hope)|March 7, 2012
A five-point checklist to help performance reports incentivize improvement and effectively guide patientsMark W Friedberg, Cheryl L Damberg
Annals of Hematology|July 3, 1999
High-dose therapy and stem cell transplantation in follicular lymphomaJ W Friedberg, A S Freedman
Expert Review of Anticancer Therapy|January 30, 2004
Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphomaJonathan W Friedberg, Richard I Fisher
Current Treatment Options in Oncology|August 19, 2006
Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphomaJonathan W Friedberg, Arnold S Freedman
Hematology/Oncology Clinics of North America|August 31, 2020
Key Clinical and Translational Research Questions to Address Unmet Needs in Mantle Cell LymphomaThomas D Rodgers, Jonathan W Friedberg
Pageof 36

Showing results (11-20 of 353) with videos related to

Sort By:
Pageof 36
The Oncologist|October 8, 2003
PET scans in the staging of lymphoma: current statusJonathan W Friedberg, Vaseem Chengazi
Current Hematologic Malignancy Reports|April 29, 2010
Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphomaManzurul A Sikder, Jonathan W Friedberg
Hematology/Oncology Clinics of North America|October 29, 2008
Diffuse large B-cell lymphomaJonathan W Friedberg, Richard I Fisher
Future Oncology (London, England)|January 15, 2021
Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomasPatrick M Reagan, Jonathan W Friedberg
Seminars in Hematology|April 3, 2008
Non-myeloablative radioimmunotherapy for non-Hodgkin's lymphomaJulia Schaefer-Cutillo, Jonathan W Friedberg
Health Affairs (Project Hope)|March 7, 2012
A five-point checklist to help performance reports incentivize improvement and effectively guide patientsMark W Friedberg, Cheryl L Damberg
Annals of Hematology|July 3, 1999
High-dose therapy and stem cell transplantation in follicular lymphomaJ W Friedberg, A S Freedman
Expert Review of Anticancer Therapy|January 30, 2004
Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphomaJonathan W Friedberg, Richard I Fisher
Current Treatment Options in Oncology|August 19, 2006
Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphomaJonathan W Friedberg, Arnold S Freedman
Hematology/Oncology Clinics of North America|August 31, 2020
Key Clinical and Translational Research Questions to Address Unmet Needs in Mantle Cell LymphomaThomas D Rodgers, Jonathan W Friedberg
Pageof 36